AZN Jul 2023 60.000 put
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:54AM EDT. Market open.
| Previous Close | 1.0000 |
| Open | 1.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 60.00 |
| Expire Date | 2023-07-21 |
| Day's Range | 1.0000 - 1.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
- Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
© 2023 Yahoo. All rights reserved.
